The strength in the big-cap drug stock names today, names like Lilly (LLY) and Bristol-Myers (BMY) and Johnson & Johnson (JNJ) almost feels program-like. It's like someone said, "Let's go buy an ETF with drug stocks." (Lilly is part of TheStreet's Action Alerts PLUS portfolio.)
It makes you wonder how much of this market really is dominated by ETFs and how much the ETFs are dominated by machines, not people.
My friend and writing partner Matt Horween and I were marveling about how little emotion there is to this rally. How methodical it all is.
We speculate that it's all machine-to-machine and not much more than that.
The machines are in charge.
I am sure tons of other groups are responding similarly. I see it in anything auto-related but I can't see the ETF doing it. The biotechs fit.
Perhaps even FANG fits, if you want to take the other side, the short side.
It's kind of a meaningless rally, but it's occurring instead of what would be an expected selloff.
Bullish victory.
Last Chance to Join Jim Cramer Oct. 28 for Just $95 a Person
Jim Cramer will host CNBC's Jon Najarian, TD Ameritrade's JJ Kinahan, famed analytics expert Marc Chaikin and other market mavens on Oct. 28 in New York City to share successful strategies for active investors.
You can join them as they discuss how smart investors can make the most of options trading, futures contracts, fundamental and quantitative analysis and great ETFs to buy right now. Participants will also get a chance to meet Jim and other panelists and take photos.
When: Saturday, Oct. 28, 8 a.m.-3 p.m. ET
Where: The Harvard Club of New York, 35 W. 44th St., New York, N.Y.
Cost: Special sale price: $95 per person if you book by midnight ET on Monday, Oct. 2. (Normal price: $250)
Click here for the full conference agenda or to reserve your seat now.
